Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03976843 | Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer | active not recruiting | Phase 2 | 175 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05502315 | Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer(CANOPY) | active not recruiting | Phase 2 | 47 | Rana McKay, MDOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT05800665 | A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer | recruiting | Phase 1 | 210 | Genentech, Inc.INDUSTRY | 7 | Sep 8, 2026 | clinicaltrials |
| NCT06067295 | Longitudinal Advanced Prostate Cancer Cohort (LAPCC) | recruiting | — | 300 | University of Southern CaliforniaOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06690970 | Prostate Specific Membrane Antigen PET/CT Imaging in PSMA-Related Disease Patients | recruiting | — | 500 | Tianjin Medical UniversityOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07224009 | Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT) | recruiting | Phase 2 | 60 | University of ArkansasOTHER | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07735377 | A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-6914 Injection in Participants With Prostate Cancer | recruiting | Phase 1 | 118 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT07807293 | Radioguided Salvage Pelvic Node Dissection in Oligometastatic Prostate Cancer - SALVAGE(SALVAGE) | not yet recruiting | Phase 2 | 62 | University of British ColumbiaOTHER | 0 | Sep 8, 2026 | clinicaltrials |
| NCT01366144 | Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction | active not recruiting | Phase 1 | 94 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04597359 | To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring | active not recruiting | Phase 2 | 360 | ECOG-ACRIN Cancer Research GroupNETWORK | 3 | Sep 4, 2026 | clinicaltrials |
| NCT04821622 | Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC | active not recruiting | Phase 3 | 599 | PfizerINDUSTRY | 27 | Sep 4, 2026 | clinicaltrials |
| NCT06384222 | Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone | active not recruiting | Phase 2 | 32 | Ivan de Kouchkovsky, MDOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT06465069 | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors(NEXUS-01) | recruiting | Phase 1 | 420 | Eli Lilly and CompanyINDUSTRY | 8 | Sep 4, 2026 | clinicaltrials |
| NCT06555796 | Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer | active not recruiting | Phase 1 | 50 | AmgenINDUSTRY | 2 | Sep 4, 2026 | clinicaltrials |
| NCT07542379 | The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer | recruiting | Early Phase 1 | 13 | FindCure Biosciences (ZhongShan) Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07567846 | A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer | recruiting | Phase 1 / Phase 2 | 260 | Genentech, Inc.INDUSTRY | 3 | Sep 4, 2026 | clinicaltrials |
| NCT07661641 | A Study of [177Lu]Lu-A9-0631 and [225Ac]Ac-A9-0642 With [68Ga]Ga-A9-6217 or [177Lu]Lu-A9-0631 Imaging in GRPR+ Solid Tumors | recruiting | Phase 1 | 115 | Alpha-9 Oncology USA Inc.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07751133 | Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer(ENHANCE) | recruiting | Phase 3 | 1,500 | University College, LondonOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07803653 | IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer | not yet recruiting | Phase 1 | 20 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT07804030 | AI-Assisted Patient Support in mHSPC(LUMINOUS) | not yet recruiting | N/A | 160 | Fudan UniversityOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT01410942 | Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy | active not recruiting | Phase 2 | 175 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT03173924 | 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer | active not recruiting | Phase 2 | 96 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT04633252 | A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06096870 | Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy | recruiting | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06138067 | Patient Navigation Program to Improve Clinical Trial Enrollment in Cancer Patients | recruiting | N/A | 90 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06515613 | A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 | 156 | Context Therapeutics Inc.INDUSTRY | 2 | Sep 3, 2026 | clinicaltrials |
| NCT06909825 | FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | active not recruiting | Phase 2 | 85 | Fusion Pharmaceuticals Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07005154 | A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer | recruiting | Phase 2 | 218 | Astellas Pharma Global Development, Inc.INDUSTRY | 12 | Sep 3, 2026 | clinicaltrials |
| NCT07285694 | AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC) | active not recruiting | Phase 1 / Phase 2 | 190 | Arsenal Biosciences, Inc.INDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07287150 | A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer(InavoPC) | recruiting | Phase 2 | 100 | Hoffmann-La RocheINDUSTRY | 12 | Sep 3, 2026 | clinicaltrials |
| NCT07545811 | Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 | 43 | Janux TherapeuticsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07578519 | Radiation Treatment of the Prostate That is Specially Adjusted for Each Person | recruiting | Phase 2 | 50 | AHS Cancer Control AlbertaOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07674225 | Dose-dEscalated MR-Guided Radiotherapy for Localized Prostate Cancer(DESTINATION 2) | active not recruiting | N/A | 24 | Sunnybrook Health Sciences CentreOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07685249 | Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment(RESTORE-PC) | not yet recruiting | N/A | 30 | Duke UniversityOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07723248 | A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)(Himalayas-1) | recruiting | Phase 3 | 600 | ORIC PharmaceuticalsINDUSTRY | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07801664 | Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer | recruiting | Phase 2 | 90 | NYU Langone HealthOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07802847 | Innovative and Cooperative Pathway Integrating Oncogeriatric, Pharmaceutical and Pharmacological Follow-up in Elderly Patients.(POG) | not yet recruiting | Phase 4 | 794 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT03181867 | 18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer | active not recruiting | Phase 2 | 360 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03762759 | Fluciclovine F18 or Ga68-PSMA PET/CT to Enhance Prostate Cancer Outcomes | active not recruiting | Phase 2 | 140 | Emory UniversityOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04188535 | Serial MRI Scans During Radiation Therapy(RELAY) | recruiting | N/A | 149 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04997018 | A Study of MRI-guided High-dose Radiation Therapy in Prostate Cancer | active not recruiting | Phase 2 | 91 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05334069 | Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | recruiting | — | 2,000 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06632977 | Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial(PREDICT) | recruiting | Phase 2 | 474 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06931340 | Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial | recruiting | Phase 3 | 1,260 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06995898 | The Vanguard Study: Testing a New Way to Screen for Cancer | recruiting | N/A | 24,000 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07192614 | A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer(ACTIVATED-4-PC) | recruiting | Phase 1 / Phase 2 | 52 | AstraZenecaINDUSTRY | 9 | Sep 2, 2026 | clinicaltrials |
| NCT07200830 | Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial | recruiting | Phase 3 | 1,524 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07609225 | Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy | not yet recruiting | Early Phase 1 | 15 | University of Wisconsin, MadisonOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07796490 | Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 30 | The Methodist Hospital Research InstituteOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07800390 | proState Cancer Health Education to pRomote Early sreENing Uptake (SCREEN): A Pilot Randomised Control Trial(SCREEN) | not yet recruiting | N/A | 74 | Teesside UniversityOTHER | 0 | Sep 2, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Sep 8, 2026source: clinicaltrials